All In Biotech

Drug Trial Radar · NCT05502549

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia

A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability,and Pharmacokinetics of Single and Multiple Ascending Oral Doses of CB03-154 in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Feb 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

56

Actual

Start

Nov 29, 2022

Primary completion

Nov 9, 2023

Study completion Dec 15, 2023

Sponsor

Sponsor type
Industry
First posted
Aug 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Epilepsy.

Conditions

  • Healthy Volunteers

Interventions

  • CB03-154Drug

    CB03-154 tablet once daily.

  • PlaceboDrug

    Placebo tablet once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of CB03-154 following single and multiple ascending oral dose administration.Time frame: From the signing of the consent form until 30 days following the last dose of the study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Limited

    Melbourne, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.